Currently there are no upcoming events.
Hosted by the Cancer Research Institute this intimate, invitation-only event for media and health care investment analysts will explore what’s next in the IO field.
Drs. Jill O'Donnell-Tormey and Vanessa M. Lucey are participating in panel discussions at Cancer Progress.
Laura Peace, Consultant, Head of Clinical Alliances, Clinical Accelerator, participates in a panel discussion, 10:30 a.m.-11:15 a.m.
Update on a CRI-funded pancreatic cancer trial led by Robert H. Vonderheide, M.D., D.Phil, on March 31 at 2:27 p.m.
CEO Jill O’Donnell-Tormey, Ph.D., participates in the Women in Science panel on March 3, 2019 at 2:30 p.m.
CRI scientists present at the Annual Meeting of the American Society of Clinical Oncologists. CRI provides a daily recap of new work coming out of the conference.
CRI-funded and -affiliated scientists and clinicians showcased at the American Association of Cancer Research Annual Meeting on April 14-18, 2018, in Chicago.
On April 12, our chief medical officer, Aiman Shalabi, is a featured expert on the panel, “Immuno-Oncology: Challenges & Opportunities”.
Dr. Jill O’Donnell-Tormey, CEO and director of scientific affairs, participates in the 'Weaponizing Your Own Body' panel on Tuesday, March 20, 2018 at 7:45 am.
Dr. Vanessa Lucey, associate director, CRI Venture Fund & Clinical Accelerator, speaks during the "Back to Basics" session on January 23, 2018 at 2:00 p.m.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
We spoke with Susanne Baumeister, M.D., about the current treatment landscape in childhood cancer, including immunotherapy and clinical trial options.
Dr. Michel Sadelain discusses what’s next in CAR T cell therapy, including the remarkable benefits and the challenges ahead for this incredibly promising immunotherapy approach.